Compare AUGO & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUGO | BLTE |
|---|---|---|
| Founded | 1946 | 2018 |
| Country | United States | United States |
| Employees | 1462 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.6B |
| IPO Year | N/A | 2021 |
| Metric | AUGO | BLTE |
|---|---|---|
| Price | $82.00 | $156.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $67.60 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 741.1K | 104.3K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $91.05 | N/A |
| Revenue Next Year | $17.09 | $492.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.55 | $56.68 |
| 52 Week High | $110.32 | $200.00 |
| Indicator | AUGO | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 42.93 | 42.14 |
| Support Level | $65.01 | $148.06 |
| Resistance Level | $90.19 | $161.28 |
| Average True Range (ATR) | 4.37 | 6.08 |
| MACD | -2.57 | -1.09 |
| Stochastic Oscillator | 10.83 | 9.37 |
Aura Minerals Inc is a mid-tier gold and copper production company focused on the development and operation of gold and base metal projects in the Americas. The company's operating segments include: Minosa Mine, Apoena Mine, the Aranzazu Mine, Almas Mine, Borborema Mine and Serra Grande Mine. It derives maximum revenue from Aranzazu Mine. The company's growth projects include: Matupa in Brazil, and Era Dorada in Guatemala. whereas its exploration projects include: Carajas, in Brazil, and Tolda Fria in Colombia.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.